Literature DB >> 33667359

Targeting Energy Metabolism in Cancer Stem Cells: Progress and Challenges in Leukemia and Solid Tumors.

Courtney L Jones1, Anagha Inguva2, Craig T Jordan3.   

Abstract

Malignant stem cells have long been considered a key therapeutic target in leukemia. Therapeutic strategies designed to target the fundamental biology of leukemia stem cells while sparing normal hematopoietic cells may provide better outcomes for leukemia patients. One process in leukemia stem cell biology that has intriguing therapeutic potential is energy metabolism. In this article we discuss the metabolic properties of leukemia stem cells and how targeting energy metabolism may provide more effective therapeutic regimens for leukemia patients. In addition, we highlight the similarities and differences in energy metabolism between leukemia stem cells and malignant stem cells from solid tumors.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Year:  2021        PMID： 33667359      PMCID： PMC7951949          DOI： 10.1016/j.stem.2021.02.013

Source DB:  PubMed          Journal:  Cell Stem Cell        ISSN： 1875-9777            Impact factor:   24.633


  164 in total

Review 1.  Acute myeloid leukemia.

Authors:  B Löwenberg; J R Downing; A Burnett
Journal:  N Engl J Med       Date:  1999-09-30       Impact factor: 91.245

2.  AKT1 and AKT2 maintain hematopoietic stem cell function by regulating reactive oxygen species.

Authors:  Marisa M Juntilla; Vineet D Patil; Marco Calamito; Rohan P Joshi; Morris J Birnbaum; Gary A Koretzky
Journal:  Blood       Date:  2010-03-30       Impact factor: 22.113

3.  The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells.

Authors:  Tamilla Nechiporuk; Stephen E Kurtz; Olga Nikolova; Tingting Liu; Courtney L Jones; Angelo D'Alessandro; Rachel Culp-Hill; Amanda d'Almeida; Sunil K Joshi; Mara Rosenberg; Cristina E Tognon; Alexey V Danilov; Brian J Druker; Bill H Chang; Shannon K McWeeney; Jeffrey W Tyner
Journal:  Cancer Discov       Date:  2019-05-02       Impact factor: 39.397

4.  Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function.

Authors:  Andrea Viale; Piergiorgio Pettazzoni; Costas A Lyssiotis; Haoqiang Ying; Nora Sánchez; Matteo Marchesini; Alessandro Carugo; Tessa Green; Sahil Seth; Virginia Giuliani; Maria Kost-Alimova; Florian Muller; Simona Colla; Luigi Nezi; Giannicola Genovese; Angela K Deem; Avnish Kapoor; Wantong Yao; Emanuela Brunetto; Ya'an Kang; Min Yuan; John M Asara; Y Alan Wang; Timothy P Heffernan; Alec C Kimmelman; Huamin Wang; Jason B Fleming; Lewis C Cantley; Ronald A DePinho; Giulio F Draetta
Journal:  Nature       Date:  2014-08-10       Impact factor: 49.962

5.  Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia.

Authors:  Marko Skrtić; Shrivani Sriskanthadevan; Bozhena Jhas; Marinella Gebbia; Xiaoming Wang; Zezhou Wang; Rose Hurren; Yulia Jitkova; Marcela Gronda; Neil Maclean; Courteney K Lai; Yanina Eberhard; Justyna Bartoszko; Paul Spagnuolo; Angela C Rutledge; Alessandro Datti; Troy Ketela; Jason Moffat; Brian H Robinson; Jessie H Cameron; Jeffery Wrana; Connie J Eaves; Mark D Minden; Jean C Y Wang; John E Dick; Keith Humphries; Corey Nislow; Guri Giaever; Aaron D Schimmer
Journal:  Cancer Cell       Date:  2011-11-15       Impact factor: 31.743

6.  BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells.

Authors:  Eleni D Lagadinou; Alexander Sach; Kevin Callahan; Randall M Rossi; Sarah J Neering; Mohammad Minhajuddin; John M Ashton; Shanshan Pei; Valerie Grose; Kristen M O'Dwyer; Jane L Liesveld; Paul S Brookes; Michael W Becker; Craig T Jordan
Journal:  Cell Stem Cell       Date:  2013-01-17       Impact factor: 24.633

Review 7.  Cancer Stem Cells - Are Surface Markers Alone Sufficient?

Authors:  Rohit P Nagare; Smarakan Sneha; Syama Krishna Priya; Trivadi S Ganesan
Journal:  Curr Stem Cell Res Ther       Date:  2017       Impact factor: 3.828

8.  Therapeutic potential of the metabolic modulator phenformin in targeting the stem cell compartment in melanoma.

Authors:  Tiziana Petrachi; Alessandra Romagnani; Adriana Albini; Caterina Longo; Giuseppe Argenziano; Giulia Grisendi; Massimo Dominici; Alessia Ciarrocchi; Katiuscia Dallaglio
Journal:  Oncotarget       Date:  2017-01-24

9.  Targeting glutaminase 1 attenuates stemness properties in hepatocellular carcinoma by increasing reactive oxygen species and suppressing Wnt/beta-catenin pathway.

Authors:  Binghua Li; Yajuan Cao; Gang Meng; Liyuan Qian; Tiancheng Xu; Chen Yan; Ouyang Luo; Shaohe Wang; Jiwu Wei; Yitao Ding; Decai Yu
Journal:  EBioMedicine       Date:  2018-12-13       Impact factor: 8.143

10.  Characterization and targeting of malignant stem cells in patients with advanced myelodysplastic syndromes.

Authors:  Brett M Stevens; Nabilah Khan; Angelo D'Alessandro; Travis Nemkov; Amanda Winters; Courtney L Jones; Wei Zhang; Daniel A Pollyea; Craig T Jordan
Journal:  Nat Commun       Date:  2018-09-12       Impact factor: 14.919
View more
  10 in total

1.  Non-genetic determinants of malignant clonal fitness at single-cell resolution.

Authors:  Katie A Fennell; Dane Vassiliadis; Enid Y N Lam; Luciano G Martelotto; Jesse J Balic; Sebastian Hollizeck; Tom S Weber; Timothy Semple; Qing Wang; Denise C Miles; Laura MacPherson; Yih-Chih Chan; Andrew A Guirguis; Lev M Kats; Emily S Wong; Sarah-Jane Dawson; Shalin H Naik; Mark A Dawson
Journal:  Nature       Date:  2021-12-08       Impact factor: 69.504

2.  Triphenilphosphonium Analogs of Chloramphenicol as Dual-Acting Antimicrobial and Antiproliferating Agents.

Authors:  Julia A Pavlova; Zimfira Z Khairullina; Andrey G Tereshchenkov; Pavel A Nazarov; Dmitrii A Lukianov; Inna A Volynkina; Dmitry A Skvortsov; Gennady I Makarov; Etna Abad; Somay Y Murayama; Susumu Kajiwara; Alena Paleskava; Andrey L Konevega; Yuri N Antonenko; Alex Lyakhovich; Ilya A Osterman; Alexey A Bogdanov; Natalia V Sumbatyan
Journal:  Antibiotics (Basel)       Date:  2021-04-23

Review 3.  Exploring the Metabolic Landscape of AML: From Haematopoietic Stem Cells to Myeloblasts and Leukaemic Stem Cells.

Authors:  Yashar Mesbahi; Toby N Trahair; Richard B Lock; Patrick Connerty
Journal:  Front Oncol       Date:  2022-02-10       Impact factor: 6.244

4.  Apoptolidin family glycomacrolides target leukemia through inhibition of ATP synthase.

Authors:  Benjamin J Reisman; Hui Guo; Haley E Ramsey; Madison T Wright; Bradley I Reinfeld; P Brent Ferrell; Gary A Sulikowski; W Kimryn Rathmell; Michael R Savona; Lars Plate; John L Rubinstein; Brian O Bachmann
Journal:  Nat Chem Biol       Date:  2021-12-02       Impact factor: 16.174

Review 5.  Reactive Oxygen Species and Metabolism in Leukemia: A Dangerous Liaison.

Authors:  Marta Romo-González; Carla Ijurko; Ángel Hernández-Hernández
Journal:  Front Immunol       Date:  2022-06-09       Impact factor: 8.786

Review 6.  Emerging roles of purinergic signaling in anti-cancer therapy resistance.

Authors:  Michele Zanoni; Anna Pegoraro; Elena Adinolfi; Elena De Marchi
Journal:  Front Cell Dev Biol       Date:  2022-09-19

Review 7.  Mitochondrial metabolism as a potential therapeutic target in myeloid leukaemia.

Authors:  Lucie de Beauchamp; Ekaterini Himonas; G Vignir Helgason
Journal:  Leukemia       Date:  2021-09-24       Impact factor: 11.528

8.  Anti-miR-135/SPOCK1 axis antagonizes the influence of metabolism on drug response in intestinal/colon tumour organoids.

Authors:  Roya Babaei-Jadidi; Hossein Kashfi; Walla Alelwani; Ashkan Karimi Bakhtiari; Shahad W Kattan; Omniah A Mansouri; Abhik Mukherjee; Dileep N Lobo; Abdolrahman S Nateri
Journal:  Oncogenesis       Date:  2022-01-19       Impact factor: 6.524

Review 9.  Macrophages and cancer stem cells: a malevolent alliance.

Authors:  Paola Allavena; Elisabeth Digifico; Cristina Belgiovine
Journal:  Mol Med       Date:  2021-09-28       Impact factor: 6.354

10.  Potential Metabolite Markers for Pancreatic Cancer Identified by Metabolomic Analysis of Induced Cancer-Associated Fibroblasts.

Authors:  Yoshihiro Miyazaki; Nobuhito Mori; Yuka Akagi; Tatsuya Oda; Yasuyuki S Kida
Journal:  Cancers (Basel)       Date:  2022-03-08       Impact factor: 6.639
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.